$IRD

2021 Q4 Form 10-K Financial Statement

#000114036122011015 Filed on March 24, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $589.0K -$1.150M
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.414M $8.121M -$1.910M
YoY Change -174.03% 187.98% -223.23%
% of Gross Profit
Research & Development $4.736M $15.17M $8.376M
YoY Change -43.46% 128.23% 1761.33%
% of Gross Profit
Depreciation & Amortization $1.000K $4.000K -$20.00K
YoY Change -105.0% -50.0% -300.0%
% of Gross Profit
Operating Expenses $6.150M $23.29M $8.376M
YoY Change -26.58% 16.66% 316.72%
Operating Profit -$22.71M
YoY Change 13.71%
Interest Expense -$2.000K $2.000K -$8.250M
YoY Change -99.98% -99.97% -5992.86%
% of Operating Profit
Other Income/Expense, Net -$161.0K -$157.0K
YoY Change -1844.44%
Pretax Income -$6.313M -$56.69M -$20.12M
YoY Change -68.62% 130.27% 975.94%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.313M -$56.69M -$20.12M
YoY Change -68.62% 130.27% 975.94%
Net Earnings / Revenue -9625.3%
Basic Earnings Per Share -$3.82
Diluted Earnings Per Share -$352.9K -$3.82 -$1.283M
COMMON SHARES
Basic Shares Outstanding 17.30M 14.85M
Diluted Shares Outstanding 14.85M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $24.75M $24.75M $16.40M
YoY Change 50.93% 50.93% 34.21%
Cash & Equivalents $24.53M $24.53M $16.40M
Short-Term Investments $219.0K $219.0K
Other Short-Term Assets $71.00K $1.314M $26.00K
YoY Change 173.08% 3.46% 420.0%
Inventory
Prepaid Expenses $1.243M $1.243M
Receivables $0.00 $0.00
Other Receivables
Total Short-Term Assets $26.07M $26.07M $17.67M
YoY Change 47.54% 47.52% 902.72%
LONG-TERM ASSETS
Property, Plant & Equipment $10.00K $10.00K $14.00K
YoY Change -28.57% 0.0% -36.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $10.00K $10.00K $14.00K
YoY Change -28.57% 0.0% -36.36%
TOTAL ASSETS
Total Short-Term Assets $26.07M $26.07M $17.67M
Total Long-Term Assets $10.00K $10.00K $14.00K
Total Assets $26.08M $26.08M $17.68M
YoY Change 47.48% 47.49% 891.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.584M $1.584M $1.214M
YoY Change 30.48% 30.91% 254.97%
Accrued Expenses $1.733M $1.733M $1.971M
YoY Change -12.08% -12.03% 217.39%
Deferred Revenue
YoY Change
Short-Term Debt $600.0K $538.0K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.855M $3.855M $3.185M
YoY Change 21.04% 20.85% -65.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $27.96M
YoY Change -100.0% -100.0% 25318.18%
Total Long-Term Liabilities $0.00 $0.00 $27.96M
YoY Change -100.0% -100.0% 25318.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.855M $3.855M $3.185M
Total Long-Term Liabilities $0.00 $0.00 $27.96M
Total Liabilities $3.855M $3.855M $31.15M
YoY Change -87.62% -87.62% 233.36%
SHAREHOLDERS EQUITY
Retained Earnings -$89.37M -$32.68M
YoY Change 173.51% 305.65%
Common Stock $2.000K $1.000K
YoY Change 100.0% -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $22.22M $22.22M -$13.47M
YoY Change
Total Liabilities & Shareholders Equity $26.08M $26.08M $17.68M
YoY Change 47.48% 47.49% 891.14%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$6.313M -$56.69M -$20.12M
YoY Change -68.62% 130.27% 975.94%
Depreciation, Depletion And Amortization $1.000K $4.000K -$20.00K
YoY Change -105.0% -50.0% -300.0%
Cash From Operating Activities -$5.646M -$19.37M -$2.660M
YoY Change 112.26% 184.98% 54.65%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$100.0K -$100.0K -$2.460M
YoY Change -95.93% -118.52% -182.0%
Cash From Investing Activities -$100.0K -$100.0K -$2.460M
YoY Change -95.93% -118.55% -182.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $28.49M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.030M 27.61M 21.12M
YoY Change -61.98% 30.71%
NET CHANGE
Cash From Operating Activities -5.646M -19.37M -2.660M
Cash From Investing Activities -100.0K -100.0K -2.460M
Cash From Financing Activities 8.030M 27.61M 21.12M
Net Change In Cash 2.284M 8.135M 16.00M
YoY Change -85.73% -45.26% 1150.0%
FREE CASH FLOW
Cash From Operating Activities -$5.646M -$19.37M -$2.660M
Capital Expenditures $0.00
Free Cash Flow -$2.660M
YoY Change 54.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001228627
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-34079
CY2021 dei Entity Registrant Name
EntityRegistrantName
Ocuphire Pharma, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-3516358
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
37000 Grand River Avenue, Suite 120
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Farmington Hills
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
48335
CY2021 dei City Area Code
CityAreaCode
248
CY2021 dei Local Phone Number
LocalPhoneNumber
681-9815
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2021 dei Trading Symbol
TradingSymbol
OCUP
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
83840460
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18989817
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
Detroit, Michigan
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
24534000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
16399000
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2020 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
10502000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
3672000
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.82
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.82
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.28
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.28
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14852745
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14852745
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4661110
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4661110
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-7560000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2126000
CY2020 ocup Adjustments To Additional Paid In Capital Convertible Note With Bifurcated Derivative
AdjustmentsToAdditionalPaidInCapitalConvertibleNoteWithBifurcatedDerivative
971000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
6953000
CY2020 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0
CY2021 us-gaap Other Noncash Expense
OtherNoncashExpense
0
CY2020 us-gaap Other Noncash Expense
OtherNoncashExpense
492000
CY2021 ocup Non Cash Interest On Convertible Notes Related Party
NonCashInterestOnConvertibleNotesRelatedParty
0
CY2020 ocup Non Cash Interest On Convertible Notes Related Party
NonCashInterestOnConvertibleNotesRelatedParty
51000
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
873000
CY2020 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1080000
CY2020 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
8115000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1506000
CY2020 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
64000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
58000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-24620000
CY2021 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2020 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
10502000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
3672000
CY2021 ocup Non Cash Discount Amortization On Convertible Notes Related Party
NonCashDiscountAmortizationOnConvertibleNotesRelatedParty
0
CY2020 ocup Non Cash Discount Amortization On Convertible Notes Related Party
NonCashDiscountAmortizationOnConvertibleNotesRelatedParty
71000
CY2021 ocup Financing Costs Reclassified From Operating Activities To Financing Activities
FinancingCostsReclassifiedFromOperatingActivitiesToFinancingActivities
0
CY2020 ocup Financing Costs Reclassified From Operating Activities To Financing Activities
FinancingCostsReclassifiedFromOperatingActivitiesToFinancingActivities
4671000
CY2021 us-gaap Recapitalization Costs
RecapitalizationCosts
0
CY2020 us-gaap Recapitalization Costs
RecapitalizationCosts
689000
CY2021 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
CY2020 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
2014000
CY2021 us-gaap Proceeds From Hedge Financing Activities
ProceedsFromHedgeFinancingActivities
0
CY2020 us-gaap Proceeds From Hedge Financing Activities
ProceedsFromHedgeFinancingActivities
21150000
CY2021 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2020 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2197000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1769000
CY2021 ocup Payment Of Stock Issuance Costs And Financing
PaymentOfStockIssuanceCostsAndFinancing
1511000
CY2020 ocup Payment Of Stock Issuance Costs And Financing
PaymentOfStockIssuanceCostsAndFinancing
10000
CY2021 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
0
CY2020 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
506000
CY2021 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
CY2020 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
9365000
CY2021 us-gaap Stock Issued1
StockIssued1
0
CY2020 us-gaap Stock Issued1
StockIssued1
8883000
CY2021 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0
CY2020 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
100000
CY2021 us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
0
CY2020 us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
68000
CY2021 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
CY2020 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
831000
CY2021 ocup Number Of Small Molecule Product Candidates
NumberOfSmallMoleculeProductCandidates
2
CY2021 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1.0565
CY2020Q4 ocup Share Based Compensation Arrangements By Share Based Payment Award Grants In Period Third Party Valuation Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardGrantsInPeriodThirdPartyValuationWeightedAverageGrantDateFairValue
8.76
CY2020Q3 ocup Share Based Compensation Arrangements By Share Based Payment Award Grants In Period Third Party Valuation Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardGrantsInPeriodThirdPartyValuationWeightedAverageGrantDateFairValue
7.89
CY2020Q1 ocup Share Based Compensation Arrangements By Share Based Payment Award Grants In Period Straight Line Calculation Using Third Party Valuation Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardGrantsInPeriodStraightLineCalculationUsingThirdPartyValuationWeightedAverageGrantDateFairValue
1.74
CY2020Q2 ocup Share Based Compensation Arrangements By Share Based Payment Award Grants In Period Straight Line Calculation Using Third Party Valuation Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardGrantsInPeriodStraightLineCalculationUsingThirdPartyValuationWeightedAverageGrantDateFairValue
9.54
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.33
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.65
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7091878
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1.0565
CY2020Q4 ocup Number Of Directors Required To Complete Transition
NumberOfDirectorsRequiredToCompleteTransition
1
CY2021 ocup Contingent Value Rights Payment Period
ContingentValueRightsPaymentPeriod
P15Y
CY2020Q4 ocup Percentage Of Cash Consideration Payment
PercentageOfCashConsiderationPayment
0.75
CY2021 ocup Contingent Value Rights Ip Term
ContingentValueRightsIPTerm
P10Y
CY2021Q4 ocup Payments Due Under Cvr Agreement
PaymentsDueUnderCVRAgreement
91000
CY2021Q4 ocup Number Of Milestones Accrued
NumberOfMilestonesAccrued
0
CY2020Q4 ocup Number Of Milestones Accrued
NumberOfMilestonesAccrued
0
CY2020Q4 ocup Number Of Potential Milestones
NumberOfPotentialMilestones
0
CY2021Q4 ocup Number Of Potential Milestones
NumberOfPotentialMilestones
0
CY2021Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P7M
CY2021Q2 ocup Number Of Accredited Investors
NumberOfAccreditedInvestors
3
CY2021 us-gaap Depreciation
Depreciation
4000
CY2020 us-gaap Depreciation
Depreciation
8000
CY2021Q4 ocup Accrued Research And Development Services And Supplies Current
AccruedResearchAndDevelopmentServicesAndSuppliesCurrent
1081000
CY2020Q4 ocup Accrued Research And Development Services And Supplies Current
AccruedResearchAndDevelopmentServicesAndSuppliesCurrent
1440000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
488000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
320000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
84000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
186000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
80000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
25000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1733000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1971000
CY2021 us-gaap Interest Expense
InterestExpense
2000
CY2021Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
1300000
CY2021 ocup Number Of Directors Signed Waiver Agreements
NumberOfDirectorsSignedWaiverAgreements
6
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1914000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1506000
CY2021 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
21414
CY2021 ocup Number Of Board Members Granted Stock For Services
NumberOfBoardMembersGrantedStockForServices
2
CY2021 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
108000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.011
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.011
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.002
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.119
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.138
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.048
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.047
CY2021 ocup Effective Income Tax Rate Reconciliation Nondeductible Expense Acquisition Research And Development Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAcquisitionResearchAndDevelopmentPercent
0
CY2020 ocup Effective Income Tax Rate Reconciliation Nondeductible Expense Acquisition Research And Development Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAcquisitionResearchAndDevelopmentPercent
0.088
CY2021 ocup Effective Income Tax Rate Reconciliation Warrants Percent
EffectiveIncomeTaxRateReconciliationWarrantsPercent
0.153
CY2020 ocup Effective Income Tax Rate Reconciliation Warrants Percent
EffectiveIncomeTaxRateReconciliationWarrantsPercent
0.076
CY2021 ocup Effective Income Tax Rate Reconciliation Convertible Notes Percent
EffectiveIncomeTaxRateReconciliationConvertibleNotesPercent
0
CY2020 ocup Effective Income Tax Rate Reconciliation Convertible Notes Percent
EffectiveIncomeTaxRateReconciliationConvertibleNotesPercent
-0.033
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.001
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.001
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19244000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3351000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
547000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
547000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
7000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
8000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
18000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
811000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
466000
CY2021Q4 ocup Deferred Tax Assets Research And Development
DeferredTaxAssetsResearchAndDevelopment
1035000
CY2020Q4 ocup Deferred Tax Assets Research And Development
DeferredTaxAssetsResearchAndDevelopment
275000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
21700000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4600000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
21700000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
21662000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4647000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
21662000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4647000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4600000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
15700000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
2700000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1000000.0
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
300000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
3600000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
600000
CY2020Q4 ocup Deferred Tax Assets Tax Credit Carryforwards Research State And Local
DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal
0
CY2021Q4 ocup Deferred Tax Assets Tax Credit Carryforwards Research State And Local
DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0

Files In Submission

Name View Source Status
0001140361-22-011015-index-headers.html Edgar Link pending
0001140361-22-011015-index.html Edgar Link pending
0001140361-22-011015.txt Edgar Link pending
0001140361-22-011015-xbrl.zip Edgar Link pending
brhc10035368_10k.htm Edgar Link pending
brhc10035368_10k_htm.xml Edgar Link completed
brhc10035368_ex21-1.htm Edgar Link pending
brhc10035368_ex23-1.htm Edgar Link pending
brhc10035368_ex31-1.htm Edgar Link pending
brhc10035368_ex31-2.htm Edgar Link pending
brhc10035368_ex32-1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image00001.jpg Edgar Link pending
image00002.jpg Edgar Link pending
image00003.jpg Edgar Link pending
image00004.jpg Edgar Link pending
image00005.jpg Edgar Link pending
image00006.jpg Edgar Link pending
image00007.jpg Edgar Link pending
image00008.jpg Edgar Link pending
image00009.jpg Edgar Link pending
image00010.jpg Edgar Link pending
image00011.jpg Edgar Link pending
image00012.jpg Edgar Link pending
image00013.jpg Edgar Link pending
image00014.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
ocup-20211231.xsd Edgar Link pending
ocup-20211231_cal.xml Edgar Link unprocessable
ocup-20211231_def.xml Edgar Link unprocessable
ocup-20211231_lab.xml Edgar Link unprocessable
ocup-20211231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending